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In October 1999, West Nile (WN) virus was first confirmed
as the cause of illness in a horse in the Western Hemisphere.
A Suffolk County, New York, horse was 1 of 25 on Long Island
that were eventually diagnosed with WN encephalitis in 1999.
Nine (36%) of the infected horses died or were euthanized.
A limited number of veterinary diagnostic tests were
available during the 1999 outbreak. Few laboratories were
prepared to conduct diagnostic tests, in part because WN
virus is categorized as a biosafety level 3 agent (1). The United
States Department of Agriculture, Animal and Plant Health
Inspection Service (APHIS), Veterinary Services, National
Veterinary Services Laboratories (NVSL), Ames, Iowa, which
is an international veterinary reference laboratory for
diagnosis of eastern, western, and Venezuelan equine
encephalomyelitis (EEE, WEE, VEE), provided diagnostic
tests for WN virus. Plaque-reduction neutralization tests
(PRNT) of equine serum (2) and virus isolation from equine
brain or spinal cord tissues were the primary WN virus
laboratory methods available in 1999. Most submissions to
the NVSL in 1999 were coordinated by APHIS Veterinary
Services as exotic disease investigations.
Evidence gathered during the winter of 1999-2000
indicated that WN virus was still present in birds and
mosquitoes in the New York City area. In early February
2000, WN virus was isolated from a Red-tailed Hawk that
died in Westchester County, New York (3). Adult Culex
mosquitoes collected from structures in New York City during
January and February 2000 were found to be infected with
WN virus (4,5). Given these findings, epizootic levels of WN virus
activity were thought likely to recur in the summer of 2000.
The laboratory methods used to detect WN virus infection
and exposure in horses served well in the initial outbreak in
1999. However, with evidence that the virus had become
established in the northeastern United States, the number
and range of horses exposed to WN virus were expected to
increase. To facilitate detection of new equine WN virus
infections, an immunoglobulin (Ig) M-capture enzyme-linked
immunosorbent assay (MAC-ELISA) was developed. The
assay, modeled after an EEE MAC-ELISA, used an
inactivated WN virus antigen from neonatal mouse brain (6).
Serum samples collected during the 1999 WN virus outbreak
were used to validate the assay. Results of experimental
challenge of a small number of horses showed that IgM
isotype anti-WN virus antibodies became detectable 8-10
days after infection and persisted <2 months in the challenge
model (Ostlund et al., unpub. data). Based on sequential
samples collected from a few horses in the New York WN virus
outbreak in 1999, the decay of IgM antibodies in naturally
infected horses appeared to be similar (7).
Given the possibility of equine cases of WN encephalitis
recurring, a case definition was developed by APHIS Veterinary
Services in the spring of 2000. Clinical signs used in the
definition were based primarily on the 1999 experience in the
United States because descriptions of clinical equine cases of
WN encephalitis in other parts of the world were limited (8-
12). To assure comparability and consistency of results, all
diagnostic testing referred to in the case definition was required
to be performed or confirmed in the same laboratory. Because
specimens might originate from multiple states, the
laboratory designated to test all specimens was the NVSL.
We evaluated diagnostic test results in combination with
clinical observations to accurately identify cases of WN
encephalitis in horses.
Methods
Characterization of Clinical Illness
Dates of onset and signs of clinical illness were obtained
from field investigators’ interviews with animal owners or
care givers or from history forms accompanying specimens
submitted to primary or reference diagnostic laboratories.
Date of onset of illness was considered to be the first time at
which any sign of illness was observed that led to a sign
specified in the case definition.
Laboratory Tests
Specimens included serum, whole blood, cerebrospinal
fluid (CSF), brain, and spinal cord tissue. Not all submissions
included each sample type.
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Virus isolation in rabbit kidney and Vero cell cultures
was attempted from brain and spinal cord tissue samples, as
well as from whole blood (13). Two cell culture passages were
performed with each cell line, and cultures were examined
daily for cytopathic effect. WN virus isolates were confirmed
by fluorescent antibody testing of infected cell cultures with a
monoclonal antibody. In addition, virus isolation attempts for
some submissions included intracerebral inoculation of 8 to
16 neonatal mice. When examination for other equine
pathogens was indicated (e.g., virus isolates not identified as
WN virus), additional virologic tests to identify equine
herpesvirus-1 (EHV-1), EEE, WEE, or VEE were performed.
EHV-1 isolates were confirmed by fluorescent antibody (14),
and alphavirus isolates were identified by complement
fixation tests (15).
The 1999 New York avian and equine WN virus isolates
were cytopathic in cell culture and formed plaques when
cultures were overlaid with agar; a crow isolate was selected
as the NY99 prototype for the PRNT. Serum dilutions of 1:10
and 1:100 were examined for WN virus neutralizing
antibodies by PRNT in 25-cm2 flasks (2). One hundred PFU of
WN virus were used in the test. Briefly, virus-serum mixtures
were incubated at 37°C for 75 minutes and then added to
flasks containing confluent monolayers of Vero cells.
Following incubation at 37°C for 60 minutes, flasks were
overlaid with agar and incubated an additional 72 hours. A
second agar overlay containing neutral red was then added,
and the flasks were examined the following day. Plaque
reduction >90% was recorded as positive. A PRNT titer at
least 1:10 in equine serum was considered significant (16).
WN virus-specific IgM antibodies in CSF and sera were
measured by MAC-ELISA (6,13). All reagents were titrated
for optimal performance in the assay. Sera were tested in
duplicate at dilutions of 1:100 and 1:1,000; CSF was tested at
dilutions of 1:2 and 1:20 in the MAC-ELISA. Briefly,
microtiter plates (Immulon 1B, Dynex, Chantilly, VA) were
coated with anti-equine IgM (Kierkegaard & Perry
Laboratories, Gaithersburg, MD) and blocked with 5% nonfat
dry milk. Serum and CSF samples were allowed to bind to the
capture antibody overnight at 4°C. After washing, bound
equine IgM was reacted with WN virus antigen and control
antigen prepared from infected and normal neonatal mouse
brain, respectively. After incubation and washing, a
flavivirus-specific horseradish peroxidase antibody conjugate
(Centers for Disease Control and Prevention, Atlanta, GA)
was added. Bound conjugate was detected by reaction with
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) as the
enzyme substrate. The absorbance at 410 nm was measured,
and antigen-specific reactions exceeding twice the negative
control were considered positive.
Criteria for Confirmed and Probable Equine WN
Encephalitis Cases
According to the APHIS Veterinary Services WN
encephalitis case definition, a confirmed case was illness in
an equine with clinical signs plus one or more of the following:
isolation of WN virus from tissue, blood, or CSF; an associated
fourfold or greater change in PRNT antibody titer to WN virus
in appropriately timed, paired sera; or detection of both IgM
antibody to WN virus by MAC-ELISA and an elevated titer
(positive at >1:10) to WN virus antibody by PRNT in a single
serum sample.
A probable case was an equine with clinical signs, located
in a county in which WN virus has been confirmed in the
current calendar year in any population: mosquito, bird,
human, or horse  (or within 10 miles of a current-year
confirmed equine case), plus one or more of the following:
detection of IgM antibody to WN virus by MAC-ELISA but no
elevated titer (negative at 1:10) to WN virus antibody by
PRNT in a single serum sample taken <21 days after onset of
illness; positive polymerase chain reaction (PCR) for WN
virus genomic sequences in tissue, blood, or CSF; or positive
immunohistochemistry for WN virus antigen in tissue.
Clinical signs must include one or more of the following:
ataxia (including stumbling, staggering, wobbly gait, or
incoordination), inability to stand, multiple limb paralysis, or
death.
Results
From January 2000 through January 2001, samples from
approximately 360 horses for which viral encephalitis was
among the differential diagnoses were submitted to the
NVSL. Submissions originated from federal, state, universi-
ty, and private diagnostic laboratories and veterinary
practitioners. Eighty-eight submissions contained equine
brain or spinal cord tissue; 314 contained serum, CSF, or
both, with some submissions including samples for both
virologic and serologic tests. The submissions originated from
33 states, with most from the northeastern United States.
In 2000, 60 horses were classified as having a confirmed
case of WN encephalitis. Twenty-three (38%) of the 60 cases
were fatal, as the horses either died or were euthanized.
Clinically, both central nervous system (CNS) and peripheral
nervous system (PNS) signs were reported (Table). Most ill
horses were reported to be ataxic. Two other common signs
included weakness of limbs or going down with difficulty
rising. Signs more commonly reported in 2000 than in 1999
included muscle fasciculation, fever, facial paralysis, facial
twitching, teeth grinding, and blindness.
Brain tissue samples were submitted from 10 of 60
horses, and CSF was submitted from 6. WN virus was isolated
from brain tissue of seven horses that became ill in August or
September 2000. Although not included among the diagnostic
tests for WN virus case confirmation in 2000, all brain
samples were also tested for WN virus RNA by reverse
transcription (RT)-nested PCR (RT-nPCR) (17). Brain
samples from each of the seven horses yielding a WN virus
isolate, plus an additional three confirmed equine WN virus
cases, were RT-nPCR positive for WN virus RNA.
No brain samples yielded more than one viral pathogen.
However, concurrent with WN virus isolations, EEE virus
Table. Clinical signs in horses with West Nile encephalitis, 2000
  Percentage of
Clinical sign horses with sign
Ataxia 85
Weakness of limbs 48
Recumbency, difficulty rising, or both 45
Muscle fasciculation 40
Fever 23
Paralyzed or drooping lip 18
Twitching face or muzzle 13
Teeth grinding   7
Blindness   5667 Vol. 7, No. 4, July–August 2001 Emerging Infectious Diseases
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was isolated from 16 equine brain samples submitted in the
fall of 2000. The EEE-positive samples were from New Jersey,
North Carolina, South Carolina, and Virginia. EHV-1 was
isolated in June from the plasma of one horse from Vermont
with neurologic illness. WN virus serologic tests were uniformly
negative in horses from which EEE or EHV-1 was isolated.
Serum was submitted for all 60 confirmed equine WN
encephalitis cases identified in 2000. Fifty-nine of 60 horses
had demonstrable WN virus-specific IgM antibodies in acute-
phase serum samples. All six CSF samples had detectable
IgM antibodies to WN virus when tested at a dilution of 1:2,
and three of six CSF samples tested WN virus IgM-positive at
the 1:20 dilution.
Neutralizing antibody titers >1:10 were detected in 55 of
59 serum samples collected at initial visit; insufficient serum
was received from one horse to test at the 1:10 dilution by
PRNT. Acute-phase serum samples from two of four horses
that did not have detectable neutralizing antibody did have
IgM antibody to WN virus. Both these horses had fatal cases
of encephalitis, and WN virus was isolated from brain tissue.
The illnesses of two horses originally classified as
probable cases were later reclassified as confirmed based on
additional test results. The first horse was IgM positive
(>1:1,000) but PRNT negative on a serum sample taken 2
days after clinical onset; a second serum sample drawn 14
days later had a PRNT titer of >1:100. The second horse was
IgM positive (>1:1,000), but PRNT negative at 1:100 with
insufficient serum drawn on the first day of clinical illness to
test at other dilutions; a second serum sample drawn 22 days
later had a PRNT titer of 1:10. One horse met the confirmed
case definition by a greater than fourfold change in PRNT titers
in paired samples. The PRNT titer in the acute-phase serum was
1:10, and a subsequent sample had a PRNT titer of >1:100.
Cases of WN encephalitis identified in 2000 had onset of
illness from mid-August to the end of October, with 42 (70%)
of the 60 cases occurring in a 4-week period from mid-
September to mid-October (Figure). Cases were detected in
seven northeastern states, six of which had no equine cases of
WN encephalitis identified in 1999. Forty-six (77%) of the
cases were in New Jersey or New York. Horses ranged in age
from 4 months to 38 years (mean 14.0 years). Thirty-six of the
horses were male (32 geldings, 3 stallions, 1 colt), and 24 were
mares. Cases occurred in at least 11 breeds of horses.
Conclusion
The emergent nature of WN virus in the United States
necessitates reevaluation of the case definition to accommo-
date clinical observations and additional laboratory methods.
Similar to events in human medicine over the past 2 years,
valuable diagnostic experience has been acquired to facilitate
identification of WN encephalitis in the U.S. equine
population. Advances in recognition of clinical signs
associated with WN encephalitis in horses and new
laboratory diagnostic tests continue to contribute to improved
veterinary diagnostic capability.
In 1999, virus isolation and neutralizing antibody
detection tests were used to test suspected cases of equine WN
encephalitis. In 1999, WN virus was isolated from brain or
spinal cord from three horses with WN encephalitis (18).
Virus isolates were identified by reverse transcription PCR
with RNA extracted from infected cell cultures (19),
confirming WN virus as the flavivirus responsible for the
1999 equine epizootic.
In surveillance and diagnostic testing of horses possibly
exposed to WN virus in 1999, no serum samples tested from
equine submissions from New York counties outside the
outbreak area or from 22 other states contained detectable
neutralizing WN virus antibodies. To date, there is no
evidence that WN virus occurred in the U.S. equine
population before 1999.
Neutralizing antibodies to WN virus may persist for >2
years following infections in humans (8). In limited samples
collected in New York from horses that were seropositive in
1999, neutralizing antibody was commonly detected through
the following winter (7). More recent testing of the same
horses indicates that their WN virus neutralizing antibodies
have now persisted for at least 15 months (Ostlund et al.,
unpub data). Such enduring titers, while perhaps engender-
ing protection from reinfection, have the potential to
complicate serologic diagnosis of new infections in a
geographic area where WN virus activity had previously
occurred. Since all WN virus infections in equines may not
give rise to clinical disease, the serologic status of
inapparently infected horses is likely to be unknown.
Development of subsequent neurologic disease in such an
animal could be mistaken for WN virus infection based on
persistent neutralizing antibody in the serum. Transfer of
WN virus-neutralizing antibodies via colostrum from a
seropositive mare in New York to her foal was demonstrated
in the spring of 2000 (authors’ unpub. observations). Taken
together, these data indicate that detection of WN virus-
specific neutralizing antibody in a single equine serum sample
has limited diagnostic value for new infections in regions
where WN virus infections have occurred in previous years.
To assist in identification of recent WN virus infections,
the MAC-ELISA method was developed and incorporated into
the repertoire of laboratory tests conducted on equine serum
and CSF in 2000. Although the kinetics of equine IgM
antibody responses to natural WN virus infection were largely
unknown, IgM serum antibody responses were expected to
wane more rapidly than neutralizing responses to WN virus.
Confidence in confirming equine WN encephalitis cases
in the United States was enhanced by the concordance of
multiple laboratory test results, including virus isolation.
The number of WN virus isolates from horses in North
America since 1999 has exceeded all previously published
Figure. Equine cases (n=60) of West Nile encephalitis in the United
States, by week of clinical onset, 2000.668 Emerging Infectious Diseases Vol. 7, No. 4, July–August 2001
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reports of the disease in horses worldwide. Nearly all
infections of WN virus in horses in 2000 were confirmed by at
least two laboratory test methods, with the combination of
MAC-ELISA and PRNT serologic tests the most dependable
in confirming cases in living horses. Fifty-four of 60 confirmed
cases had detectable WN virus IgM and neutralizing antibody
responses in the acute-phase serum samples. For submis-
sions yielding WN virus from brain, positive WN virus RT-
nPCR, or both, IgM was consistently present in serum. Eight
of 10 submissions that were WN virus isolation positive, RT-
nPCR positive, or both had neutralizing antibody in serum at
the time of death. Convalescent-phase serums were needed to
support confirmation in three cases. When available, CSF
samples from acute-phase cases also yielded positive WN
virus IgM results, although testing at a lower dilution than
for serum was necessary.
During the 1999 equine outbreak, the primary clinical
sign reported (in 18 of 25 cases) was ataxia, either sudden or
progressive. Fever associated with clinical illness was
documented in only one horse. There were attitudinal changes
in many horses, including somnolence, listlessness, appre-
hension, depression, or periods of hyperexcitability. A greater
range of clinical signs were reported for infected horses in
2000 than in the 1999 epizootic.
For a few WN virus suspected cases, the criteria for
classification as a confirmed case were only partially met.
Illnesses in horses that had only clinical signs not included in
the 2000 case definition were not classified as cases by APHIS
Veterinary Services. Three clinically ill horses had serum
specimens with WN virus IgM titers >1:100 and PRNT titers
>1:10, but none of the signs reported were compatible with the
APHIS case definition. Although WN virus infection likely did
occur in these horses, they were not included in the WN virus
equine encephalitis cases for 2000, since their illness did not
reflect encephalitis. In addition, some suspected WN virus
cases could not be confirmed in the laboratory because of
insufficient samples.
For some horses, the clinical history and geographic
location prompted consideration of WN encephalitis but no
laboratory tests supported such a diagnosis. Multiple cases of
EEE were identified at the National Veterinary Services
Laboratory in the fall of 2000, concurrent with the WN virus
epizootic. Thus, considering other causes of equine neurologic
disease in the differential diagnosis is important.
The surveillance case definition for WN encephalitis in
equines used by APHIS Veterinary Services was developed to
be as sensitive as possible, yet minimize false-positive case
classifications. One of the primary reasons for performing
surveillance for equine WN encephalitis is to be able to meet
international obligations for disease reporting. Such disease
reports can have substantial ramifications for the
international movement of horses and other livestock. A high
level of specificity in case classification is therefore critical,
especially when detecting and reporting the first case of
disease in a given geographic area (e.g., a previously
unaffected state). Given the specificity of the case definition,
failure of a clinically ill equine to meet the criteria for a
probable or confirmed case does not completely exclude the
possibility that WN virus was the cause of illness.
Based on experience gained in 2000, some modifications
will be considered in the diagnostic tests and clinical
observations used to identify cases of WN encephalitis in
horses in 2001 and future years. Such changes include the
addition of a wider range of clinical signs, including PNS
signs and additional CNS signs. New laboratory tests will
also be incorporated, in particular RT-nPCR, which has been
shown to be accurate in detecting WN virus nucleic acid in
CNS tissues.
As the range of WN virus activity increases, prevention
and control issues for horses becomes even more important.
To date, prevention recommendations have been broad and
generally targeted at reducing sources of water for mosquito
breeding and decreasing equine exposure to biting
mosquitoes. Risk factors for equine infection with WN virus
are being evaluated through a case-control study conducted
by APHIS and animal health officials in states where equine
WN encephalitis was detected in 2000. Results of that study
may provide information for more specific recommendations
on preventing equine infections. Of most use in preventing
illness and death of equines may be a vaccine against WN
virus. Vaccines for equine use are being developed and could
be available for use as early as the summer of 2001.
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